These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17699484)

  • 1. Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen.
    Kamel Mohamed OH; Wahba IM; Watnick S; Earle SB; Bennett WM; Ayres JW; Munar MY
    Clin J Am Soc Nephrol; 2007 Jul; 2(4):694-9. PubMed ID: 17699484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease.
    Smith WB; Dowell JA; Pratt RD
    Clin Ther; 2007 Jul; 29(7):1368-80. PubMed ID: 17825688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
    Schaedeli F; Uehlinger DE
    Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
    Dager WE; King JH
    Ann Pharmacother; 2006 Jan; 40(1):9-14. PubMed ID: 16332944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
    Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
    Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring.
    de Hoog M; Mouton JW; Schoemaker RC; Verduin CM; van den Anker JN
    Clin Pharmacol Ther; 2002 May; 71(5):349-58. PubMed ID: 12011820
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tobramycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 1997 Oct; 62(4):392-9. PubMed ID: 9357390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoglycoside redistribution phenomenon after hemodialysis: netilmicin and tobramycin.
    Halstenson CE; Berkseth RO; Mann HJ; Matzke GR
    Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):50-5. PubMed ID: 3557729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
    Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
    Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis.
    Teigen MM; Duffull S; Dang L; Johnson DW
    J Clin Pharmacol; 2006 Nov; 46(11):1259-67. PubMed ID: 17050791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
    Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduction in beta2-microglobulin with super-flux versus high-flux dialysis membranes: results of a 6-week, randomized, double-blind, crossover trial.
    Pellicano R; Polkinghorne KR; Kerr PG
    Am J Kidney Dis; 2008 Jul; 52(1):93-101. PubMed ID: 18423807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adequacy of a vancomycin dosing regimen in patients receiving high-flux hemodialysis.
    Ariano RE; Fine A; Sitar DS; Rexrode S; Zelenitsky SA
    Am J Kidney Dis; 2005 Oct; 46(4):681-7. PubMed ID: 16183423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
    Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
    Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic studies on tobramycin in horses.
    Hubenov H; Bakalov D; Krastev S; Yanev S; Haritova A; Lashev L
    J Vet Pharmacol Ther; 2007 Aug; 30(4):353-7. PubMed ID: 17610409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aminoglycoside pharmacokinetic parameters in neurocritical care patients undergoing induced hypothermia.
    Mercer JM; Neyens RR
    Pharmacotherapy; 2010 Jul; 30(7):654-60. PubMed ID: 20575630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of vancomycin during high-efficiency hemodialysis.
    Klansuwan N; Ratanajamit C; Kasiwong S; Wangsiripaisan A
    J Med Assoc Thai; 2006 Jul; 89(7):986-91. PubMed ID: 16881431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients.
    Badia JR; Soy D; Adrover M; Ferrer M; Sarasa M; Alarcón A; Codina C; Torres A
    J Antimicrob Chemother; 2004 Aug; 54(2):508-14. PubMed ID: 15215224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.